IPC분류정보
국가/구분 |
United States(US) Patent
등록
|
국제특허분류(IPC7판) |
|
출원번호 |
US-0967163
(2013-08-14)
|
등록번호 |
US-8629111
(2014-01-14)
|
발명자
/ 주소 |
- Acheampong, Andrew
- Tang-Liu, Diane D.
- Chang, James N.
- Power, David F.
|
출원인 / 주소 |
|
대리인 / 주소 |
|
인용정보 |
피인용 횟수 :
4 인용 특허 :
94 |
초록
▼
Methods of treating an eye of a human or animal include administering to an eye of a human or animal a composition in the form of an emulsion including water, a hydrophobic component and a cyclosporin component in a therapeutically effective amount of less than 0.1% by weight of the composition. The
Methods of treating an eye of a human or animal include administering to an eye of a human or animal a composition in the form of an emulsion including water, a hydrophobic component and a cyclosporin component in a therapeutically effective amount of less than 0.1% by weight of the composition. The weight ratio of the cyclosporin component to the hydrophobic component is less than 0.8.
대표청구항
▼
1. A topical ophthalmic emulsion for treating an eye of a human comprising cyclosporin A in an amount of about 0.05% by weight, polysorbate 80, acrylate/C10-30 alkyl acrylate cross-polymer, water, and castor oil in an amount of about 1.25% by weight; wherein cyclosporin A is the only peptide present
1. A topical ophthalmic emulsion for treating an eye of a human comprising cyclosporin A in an amount of about 0.05% by weight, polysorbate 80, acrylate/C10-30 alkyl acrylate cross-polymer, water, and castor oil in an amount of about 1.25% by weight; wherein cyclosporin A is the only peptide present in the topical ophthalmic emulsion. 2. The topical ophthalmic emulsion of claim 1, wherein the topical ophthalmic emulsion further comprises a tonicity agent or a demulcent component. 3. The topical ophthalmic emulsion of claim 2, wherein the tonicity agent or the demulcent component is glycerine. 4. The topical ophthalmic emulsion of claim 1, wherein the topical ophthalmic emulsion further comprises a buffer. 5. The topical ophthalmic emulsion of claim 4, wherein the buffer is sodium hydroxide. 6. The topical ophthalmic emulsion of claim 1, wherein the topical ophthalmic emulsion further comprises glycerine and a buffer. 7. The topical ophthalmic emulsion of claim 1, wherein the topical ophthalmic emulsion comprises polysorbate 80 in an amount of about 1.0% by weight. 8. The topical ophthalmic emulsion of claim 1, wherein the topical ophthalmic emulsion comprises acrylate/C10-30 alkyl acrylate cross-polymer in an amount of about 0.05% by weight. 9. The topical ophthalmic emulsion of claim 1, wherein the topical ophthalmic emulsion further comprises glycerine in an amount of about 2.2% by weight, water, and a buffer. 10. The topical ophthalmic emulsion of claim 9, wherein the buffer is sodium hydroxide. 11. The topical ophthalmic emulsion of claim 1, wherein, when the topical ophthalmic emulsion is administered to an eye of a human, the blood of the human has substantially no detectable concentration of cyclosporin A. 12. The topical ophthalmic emulsion of claim 6, wherein the topical ophthalmic emulsion has a pH in the range of about 7.2 to about 7.6. 13. A topical ophthalmic emulsion for treating an eye of a human, wherein the topical ophthalmic emulsion comprises: cyclosporin A in an amount of about 0.05% by weight;castor oil in an amount of about 1.25% by weight;polysorbate 80 in an amount of about 1.0% by weight;acrylate/C10-30 alkyl acrylate cross-polymer in an amount of about 0.05% by weight;a tonicity component or a demulcent component in an amount of about 2.2% by weight;a buffer; andwater;wherein the topical ophthalmic emulsion has a pH in the range of about 7.2 to about 7.6 and wherein cyclosporin A is the only peptide present in the topical ophthalmic emulsion. 14. The topical ophthalmic emulsion of claim 13, wherein the buffer is sodium hydroxide. 15. The topical ophthalmic emulsion of claim 13, wherein the tonicity component or the demulcent component is glycerine. 16. The topical ophthalmic emulsion of claim 13, wherein, when the topical ophthalmic emulsion is administered to an eye of a human, the blood of the human has substantially no detectable concentration of the cyclosporin A. 17. The topical ophthalmic emulsion of claim 13, wherein the topical ophthalmic emulsion is effective in treating keratoconjunctivitis sicca. 18. A topical ophthalmic emulsion for treating an eye of a human, the topical ophthalmic emulsion comprising: cyclosporin A in an amount of about 0.05% by weight;castor oil in an amount of about 1.25% by weight;polysorbate 80 in an amount of about 1.0% by weight;acrylate/C10-30 alkyl acrylate cross-polymer in an amount of about 0.05% by weight;glycerine in an amount of about 2.2% by weight;sodium hydroxide; andwater;wherein cyclosporin A is the only peptide present in the topical ophthalmic emulsion. 19. The topical ophthalmic emulsion of claim 18, wherein the topical ophthalmic emulsion has a pH in the range of about 7.2 to about 7.6. 20. The topical ophthalmic emulsion of claim 1, wherein the topical ophthalmic emulsion is therapeutically effective in treating dry eye. 21. The topical ophthalmic emulsion of claim 1, wherein the topical ophthalmic emulsion is therapeutically effective in treating keratoconjunctivitis sicca. 22. The topical ophthalmic emulsion of claim 1, wherein the topical ophthalmic emulsion is therapeutically effective in increasing tear production. 23. The topical ophthalmic emulsion of claim 13, wherein the topical ophthalmic emulsion is therapeutically effective in treating dry eye. 24. The topical ophthalmic emulsion of claim 13, wherein the topical ophthalmic emulsion is therapeutically effective in increasing tear production. 25. The topical ophthalmic emulsion of claim 18, wherein the topical ophthalmic emulsion is therapeutically effective in treating dry eye. 26. The topical ophthalmic emulsion of claim 18, wherein the topical ophthalmic emulsion is therapeutically effective in treating keratoconjunctivitis sicca. 27. The topical ophthalmic emulsion of claim 18, wherein the topical ophthalmic emulsion is therapeutically effective in increasing tear production.
※ AI-Helper는 부적절한 답변을 할 수 있습니다.